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Key points:  
 There is little evidence of the therapeutic value of using antidepressants in dementia 
whatever the indication 
 A better understanding of the aetiologies underlying neuropsychiatric symptoms in 
dementia would assist the development of future treatments 
 Antidepressants have adverse effects when used in those with dementia 
 Further large scale high quality RCTs are needed to test the role of antidepressants 
in under-researched areas such as anxiety and agitation in dementia and 
discontinuation of antidepressants in dementia 
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ABSTRACT 
Objectives: Antidepressants are commonly used in dementia.  Depression is a 
frequent and important co-morbidity in dementia and antidepressants are often used 
to treat depression and more widely.  However there are questions about their utility 
in depression in dementia and other behavioural and psychological symptoms of 
dementia (BPSD).  The aim of this narrative review is to summarise the evidence on 
whether there is therapeutic value in prescribing antidepressants to people with 
dementia.  
Methods: A PubMed search was performed to identify RCTs that prescribed 
antidepressants to people with dementia, either in the treatment of BPSD 
(depression, anxiety, agitation/aggression, psychosis, apathy) or for secondary 
outcomes (quality of life, carer burden, activities of daily living, cognition, clinical 
severity, adverse events). 
Results: Thirty-six RCTs were identified (participant n=3,386). A consistent finding in 
well-designed blinded placebo controlled trials in dementia is the lack of positive 
effect of antidepressants on outcomes of interest including depression.  One large 
well-designed study has reported a significant reduction in agitation in people with 
dementia, but at the expense of clinically significant adverse events.  Otherwise 
change observed in open trials is also seen in the placebo group, suggesting any 
effect is not attributable to the prescription of antidepressants.   
Conclusions: It is striking how few data there are on indications other than 
depression.  We should question the use of antidepressants in dementia.  Definitive 
trials of clinical effectiveness of specific indications such as anxiety and agitation in 
dementia and discontinuation of antidepressants in dementia are needed.  
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INTRODUCTION 
Antidepressants are commonly used in dementia, but do they do any good?  
Depression is a frequent and important co-morbidity in dementia and 
antidepressants are often used to treat the syndrome of depression.  They are also 
used to treat other behavioural and psychological symptoms of dementia (BPSD)  
(Finkel et al., 2000) including agitation, aggression, psychosis and apathy (Burns 
and Iliffe, 2009).  There is a need for effective treatment of depression and other 
BPSD, because of their profound negative impact on individuals with dementia and 
their caregivers.  They complicate patient care (Bharucha et al., 2002), increase the 
cost of care (Beeri et al., 2002) and result in caregiver burden (Coen et al., 1997), 
rapid cognitive decline (Stern et al., 1987), impairment in activities of daily living 
(ADL) (Lyketsos et al., 1997; Mok et al., 2004) and poorer quality of life (QoL) 
(González-Salvador et al., 2000). Each of these has a profound negative impact on 
both the person with dementia and carers, so treatment is a clinical priority. 
 
Systematic reviews of the literature have generally found little or equivocal evidence 
for the effectiveness of antidepressants in the treatment of depression in dementia 
(Bains et al., 2002; Nelson and Devanand, 2011) or BPSD (Sink et al., 2005). 
Despite this, 25-42% of all those with dementia may be prescribed antidepressants 
(Pitkala et al., 2004; Snowdon et al., 2011). Due to their widespread use in the 
absence of definitive evidence of their effects and side effects in populations with 
dementia, it is important to establish their efficacy and tolerability in dementia.  No 
review to date has taken account of the multiple potential targets for antidepressants 
in dementia.  In this narrative review we seek to present RCT data to enable a 
balanced appraisal of the use of antidepressants in dementia across indications.  
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REVIEW 
This paper is a narrative review. In comparison to a systematic review, a  narrative 
review is less formal and systematic and subjective methods are used to interpret 
information, which is then summarised subjectively and narratively (Klassen et al., 
1998).  We chose this format rather than that of a systematic review because of the 
nature of the data available and the breadth of the question posed.  Formal 
systematic review methodology is not well suited to answering multiple questions in 
a broad literature of variable quality.   
 
We performed a literature search using the PubMed database for peer-reviewed 
publications available on 9 December 2015, without language restrictions. The 
following search terms were used; ‘depression’, ‘dementia’, ‘Alzheimer’s disease’, 
‘antidepressant’, ‘SSRIs’, ‘anxiety’, ‘agitation’, ‘aggression’,  ‘psychosis’, ‘apathy’, 
‘behavioural and psychological symptoms’, ‘BPSD’ and ‘CSDD’ (Cornell Scale for 
Depression in Dementia). Results were filtered to include only RCTs. For inclusion, 
RCTs were required to have an antidepressant treatment arm being administered to 
a dementia population. Trials were excluded if the sample population were 
cognitively healthy or had mild cognitive impairment (MCI). In trials with both 
dementia and non-dementia participants, outcomes for the dementia subgroup 
needed to be reported separately. There was no exclusion criteria based on age, 
gender or dementia subtype. Trials were excluded if they did not use validated 
measures of the following outcomes: depression, agitation/aggression, anxiety, 
apathy, psychosis, cognitive status, functional status, carer burden, QoL, clinical 
severity and global BPSD.  Systematic reviews and meta-analyses were sought 
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through PubMed and The Cochrane Library to provide guidance on the narrative and 
to identify additional studies that may have been missed in the initial search. Titles 
and abstracts were independently screened by two authors (NF and LM) before full-
texts were obtained and screened. 
 
Following exclusions, the search identified thirty-four RCTs; two additional RCTs 
were identified after reading relevant literature (Finkel et al., 2004; Gaber et al., 
2001). A summary of outcome measures of identified RCTs were extracted (Table 
1). Information on sample population, intervention type and results associated with 
antidepressant treatment and how they compared to a placebo group or comparator, 
were also extracted (Table 2). All data were extracted by a single author (NF) and 
independently verified by a second author (LM). In addition to the RCTs, we 
identified three Cochrane reviews (Bains et al., 2002; Martinón-Torres et al., 2004; 
Seitz et al., 2011) and six systematic reviews (Henry et al., 2011; Leong, 2014; 
Nelson and Devanand, 2011; Sepehry et al., 2012; Sink et al., 2005; Thompson et 
al., 2007). 
 
Risk of bias was subsequently assessed using The Cochrane Collaboration’s tool for 
assessing risk of bias (Higgins et al., 2011) by NF and independently confirmed by 
SB. The tool was used as means to describe the risk of bias and it was not used a 
means to exclude any studies. The majority of studies were deemed as having 
‘unclear’ or ‘low’ risk of bias across all elements.  Many of the unclear judgements 
were as a result of poor reporting. For example, the majority of studies reported as 
“double-blind” did not describe the steps they took to ensure this and whether it was 
successfully maintained. Nine studies were deemed to have at least 1 element of 
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high risk of bias. One study (Moretti et al., 2002) had multiple elements judged as 
having a high risk of bias; this was largely due to the fact it was not double-blinded. 
Three studies were judged to have low risk of bias across all elements: HTA-SADD 
(Banerjee et al., 2013, 2011), DIADS-II (Drye et al., 2011; Martin et al., 2006; 
Rosenberg et al., 2010; Weintraub et al., 2010), and CitAD (Peters et al., 2015; 
Porsteinsson et al., 2014) (Table 3). 
 
Antidepressants for depression in dementia 
Apart from a few exceptions (e.g. Choe et al., 2015; Pollock et al., 2002), it is clear 
that most individuals recruited into trials of selective serotonin reuptake inhibitor 
(SSRI) antidepressants or serotonin-noradrenaline reuptake inhibitors (SNRIs) have 
experienced reduced depressive symptoms from baseline to endpoint (Banerjee et 
al., 2011; Bergh et al., 2012; Karlsson et al., 2000; Katona et al., 1998; Lyketsos et 
al., 2003, 2000b; Magai et al., 2000; Moretti et al., 2002; Mowla et al., 2007; Nyth et 
al., 1992; Nyth and Gottfries, 1990; Petracca et al., 2001; Taragano et al., 1997; 
Nyth and Gottfries, 1990). However, the same magnitude of change is seen in the 
placebo group so these decreases in depression are not attributable to the 
antidepressants. Two trials found a significant improvement above that of placebo 
(Lebert et al., 2004; Lyketsos et al., 2003); they were both small in sample size and 
Lebert and colleagues did not use a measure of depression validated in dementia 
(Lebert et al., 2004).   
 
The quality of the studies available is an important consideration. The Cochrane 
review Antidepressants for treating depression in dementia (Bains et al., 2002) 
identified only four studies which reported sufficiently detailed results to enter into a 
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meta-analysis, with a total of 137 subjects. The review concluded that the evidence 
for clinical effectiveness of antidepressants for depression in dementia was 
equivocal and weak and that the small possibility of positive effect was driven by the 
highly positive DIADS study of sertraline (Lyketsos et al., 2003). Since that review, 
the much larger DIADS-II study (Drye et al., 2011; Rosenberg et al., 2010; Weintraub 
et al., 2010) has yielded robust data demonstrating that sertraline is not superior to 
placebo in the treatment of depression in dementia. They found no benefit of 
sertraline over placebo at 12 or 24 weeks. When these data are added to those from 
the HTA-SADD Trial (Banerjee et al., 2013, 2011), which found no superiority of 
sertraline over placebo in a larger sample (n=326) at 13 and 39 weeks of treatment, 
the evidence base suggests that SSRI antidepressants do not appear to work as a 
treatment for depression in dementia. 
 
There are a number of older and generally smaller trials which have investigated 
tricyclic antidepressants (TCAs) and Monoamine Oxidase Inhibitors (MAOIs) 
(Petracca et al., 1996; Reifler et al., 1989; Roth et al., 1996; Teri et al., 1991). The 
quality of these studies reflects their age; the outcome measures used are not 
developed or validated for use in dementia; these studies often do not meet the 
quality thresholds needed for inclusion in modern systematic reviews. Two RCTs 
explored the effects of imipramine on depression in dementia and found no benefit 
over placebo (Teri et al., 1991; Reifler et al., 1989). In a very small double-blind 
cross-over RCT of clomipramine, participants receiving the treatment significantly 
improved in Hamilton Depression Rating Scale (HDRS) score and remission rate, 
compared to placebo (Petracca et al., 1996). Similarly, Roth and colleagues found 
the MAOI, moclobemide had some effect in improving HDRS scores in a mixed 
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group of cognitive impairment in comparison to placebo (Roth et al., 1996). Quality 
issues in the design of these studies as well as the appreciable side effects of these 
classes of antidepressants, mean that their clinical utility remains unproven.  
 
Few trials have investigated the effects of newer, non-SSRI antidepressants on 
depression in dementia. The HTA-SADD trial, found that treatment with mirtazapine, 
a noradrenergic and specific serotonergic antidepressant (NaSSA), was no better 
than treatment with placebo over 13 and 39 weeks (Banerjee et al., 2013, 2011). 
Fuchs and colleagues reported that the tetracyclic antidepressant maprotiline was 
significantly better at improving depression scores compared to placebo on the 
Geriatric Depression Scale (GDS; p=0.09) (Fuchs et al., 1993). Caution should be 
taken interpreting this on methodological grounds; statistical significance was set at 
10% rather than the usual 5% level and the GDS has limitations in populations with 
dementia (Burke et al., 1989; Kørner et al., 2006). 
 
A balanced appraisal of the evidence suggests, taking into account the 
methodological limitation of older studies, that the antidepressants tested to date 
show no convincing advantage over placebo for the treatment of depression in 
dementia. 
 
Antidepressants for anxiety in dementia 
Despite anxiety being common in dementia (Badrakalimuthu and Tarbuck, 2012) and 
previous recommendations to use antidepressants in its treatment (Sink et al., 2005), 
few RCTs have investigated the effects of antidepressants on anxiety in dementia. In 
four trials, treatment had no significant effect on anxiety score over placebo (Lebert 
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et al., 2004; Teranishi et al., 2013;  Nyth et al., 1992; Nyth and Gottfries, 1990). In all 
four trials anxiety was only measured using subscale of a broader assessment tool. 
One other RCT used a specific and validated measure of anxiety (Petracca et al., 
2001) but again found no significant improvement in anxiety scores compared with 
placebo.   
 
What is striking is the lack of large well-designed trials designed to generate a 
definitive appraisal of the clinical effectiveness of antidepressants for anxiety in 
dementia. Despite its reported impact on those with dementia and their carers, the 
management of anxiety in dementia has attracted little attention in terms of research 
and/or funding. This area would benefit from further research. 
 
Antidepressants for agitation in dementia 
Agitation, defined as inappropriate verbal, vocal or motor activity, which is not an 
expression of unmet need, and which encompasses physical and verbal aggression 
(Cohen-Mansfield and Billig, 1986), is particularly problematic in dementia. It can 
affect 50% of people with AD over a month (Okura et al., 2010) and appears to 
persist (Ryu et al., 2005). It is associated with deteriorating relationships with family 
and professional carers, institutionalisation, increased costs of care, carer burden, 
carer burnout and decreased QoL (Okura et al., 2010; Ryu et al., 2005; Wetzels et 
al., 2010). As such, it is a legitimate target for intervention (Banerjee, 2009). 
Antipsychotic medication, the current mainstay of drug treatment for agitation and 
aggression in dementia, has only a limited positive effect in treating symptoms and 
can cause significant harm to people with dementia (Banerjee, 2009; Gill et al., 
2007).  
11 
 
 
Despite much research, no other drugs have a proven positive role in the treatment 
of agitation, but antidepressants have been considered as a possible alternative to 
antipsychotics (Tariot et al., 1998, 1995). Sulzter and colleagues compared the 
efficacy of trazodone to haloperidol, in the treatment of agitation in dementia (Sultzer 
et al., 2001, 1997). Results indicated that they were equally effective overall. Similar 
findings have been reported comparing sertraline to haloperidol treatment (Gaber et 
al., 2001).  However, the small sample sizes (n=28 and 23 respectively) and lack of a 
placebo group in both trials, limit the interpretation of these findings. They are not 
likely to have been powered appropriately to make valid inferences of equivalence of 
effect.   
 
Two studies have reported that antidepressants reduce agitation compared to 
placebo in dementia (Pollock et al., 2002; Porsteinsson et al., 2014), however much 
of the literature has found no significant treatment effect (Auchus and Bissey-Black, 
1997; Finkel et al., 2004; Lanctôt et al., 2002; Magai et al., 2000; Pollock et al., 2007; 
Sultzer et al., 2001, 1997; Teranishi et al., 2013; Teri et al., 2000). One potential 
limitation of the majority of these studies (all but Auchus and Bissey-Black, 1997; 
Porsteinsson et al., 2014; Sultzer et al., 2001, 1997), is that they treated agitation as 
a continuous variable and did not require participants to have clinically significant 
agitation on enrolment. 
 
The best trial in this area is the large (n=186) well-designed CitAD trial (Peters et al., 
2015; Porsteinsson et al., 2014). In this 9 week RCT comparing citalopram with 
placebo, all participants had probable AD and clinically significant agitation. The trial 
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found that citalopram led to a reduction in agitation, measured by the agitation 
subscale of the Neurobehavioral Rating Scale (−0.93 (95% CI, −1.80 to −0.06), 
p=0.04). CitAD provides evidence that 30mg citalopram daily has a positive effect on 
agitation in dementia.  It also confirms safety concerns for citalopram (US FDA, 
2012). The adverse cardiac effects identified in the trial, and to a lesser extent the 
cognitive impairment observed, is likely to limit use in clinical practice (National 
Institute for Health and Care Excellence, 2014). The CitAD trial is however 
encouraging, this evidence of antidepressant efficacy supports the need for further 
research and is a proof of the concept that antidepressants as a class of drugs may 
have a role in the management of agitation in dementia. 
 
Antidepressants for psychosis in dementia 
Psychotic symptoms (hallucinations and delusions) may affect 60% of those with 
dementia (Ballard et al., 1995). Antipsychotic medication is traditionally used to treat 
psychotic symptoms in dementia, in line with treatment practice in those without 
cognitive impairment. However, as noted above antipsychotics are associated 
adverse events in dementia including an increase in mortality (Gill et al., 2007; 
Schneider et al., 2005). In light of this, there is a desire to test alternate treatments 
such as antidepressants. In a recent RCT (Teranishi et al., 2013), 82 patients with 
dementia and neuropsychiatric symptoms were randomly assigned to receive 
risperidone, fluvoxamine or yokukansa (a traditional Japanese herbal remedy) for 8 
weeks. Those receiving fluvoxamine had a significant improvement in delusion but 
not hallucination scores over the trial, but there were no between-group effects on 
either delusion or hallucination scores and no placebo with which to compare the 
effects.  
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Other trials have reported similar findings (Bergh et al., 2012; Lebert et al., 2004; 
Pollock et al., 2007, 2002; Sultzer et al., 2001) but these are largely secondary 
analyses of RCTs designed to investigate other primary hypotheses. So participants 
were generally not selected on the basis of having psychosis in dementia, the 
measures chosen often lack in detail and the trials do not include a placebo group 
(all but Pollock et al., 2002). An exception is the small study by Levkovitz and 
colleagues where 20 participants with AD and psychotic symptoms were randomly 
assigned perphenazine with either fluvoxamine or placebo in a 6 week cross-over 
RCT (Levkovitz et al., 2001). Those receiving adjunctive fluvoxamine significantly 
improved scores on the Brief Psychiatric Rating Scale (BPRS) compared to placebo.  
 
At present, the evidence base for the value of antidepressant use for psychosis in 
dementia is weak with little suggestion of positive effect.  There would be value in 
further research in this area. 
 
Antidepressants for apathy in dementia 
Apathy is a core element of depression and so separating it from depression is 
problematic.  However, there have been observations of apathy without apparent 
depression in dementia, so apathy has been proposed as a behavioural syndrome 
characterized by a decrease in interest, motivation, or initiation of action (van 
Reekum et al., 2005). Apathy so defined is a common neuropsychiatric syndrome in 
AD, with a prevalence of 92% in severe AD (Mega et al., 1996). There is little 
evidence to support the notion that antidepressants might have a specific effect on 
apathy in dementia. Bergh and colleagues discontinued SSRI medication for 25 
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weeks in 63 patients with AD, VaD or mixed dementia with neuropsychiatric 
symptoms (Bergh et al., 2012). Apathy scores were found not to differ significantly 
between those that discontinued or continued SSRI treatment. Fluvoxamine 
(Teranishi et al., 2013), trazodone (Lebert et al., 2004), and citalopram (Pollock et 
al., 2002) have also been reported to have no effect on apathy scores.   
 
No trial to date has defined participants by clinical level of apathy at baseline. There 
is little evidence for a role of antidepressants in the specific treatment of apathy in 
dementia.  
 
Antidepressants and carer burden in dementia 
BPSD is associated with carer burden (Burns and Rabins, 2000; Coen et al., 1997). 
Few trials have explored the impact of antidepressants given to the person with 
dementia on carer burden; in most no significant treatment effects were observed 
(Auchus and Bissey-Black, 1997; Banerjee et al., 2013, 2011; Finkel et al., 2004; 
Lyketsos et al., 2003; Teri et al., 2000). Two studies reported that antidepressants 
had a positive effect on carer burden (Moretti et al., 2002; Porsteinsson et al., 2014) 
both also showed the antidepressant improved BPSD, suggesting a pathway to relief 
of carer burden via the relief of BPSD in the person with dementia.  In terms of 
objective burden, HTA-SADD found those randomised to mirtazapine required half 
the unpaid carer time, compared with those receiving placebo or sertraline (Romeo 
et al., 2013). It is possible this effect was mediated via the putative ability of 
mirtazapine to ameliorate sleep disturbance. Improvements in sleep could potentially 
release carer time directly and address an important source of carer distress. In this 
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way an antidepressant might have a general effect, beneficial for both the patient 
and the carer, without exerting a specific antidepressant effect.  
 
Antidepressants and activities of daily living in dementia 
Function in terms of ADL is a common secondary outcome measure when 
investigating the effects of antidepressants in dementia. All but two studies suggest 
that antidepressants do not further impair ADL in dementia (Banerjee et al., 2013, 
2011; Bergh et al., 2012; Finkel et al., 2004; Lyketsos et al., 2003, 2000a; Moretti et 
al., 2002; Petracca et al., 1996, 2001; Porsteinsson et al., 2014; Reifler et al., 1989; 
Teranishi et al., 2013; Weintraub et al., 2010).  One reported a positive effect (Mowla 
et al., 2007) and one a negative effect (Teri et al., 2000). On balance there is no 
evidence at present to suggest that antidepressants have a positive or negative 
effect on ADLs in dementia. 
 
Antidepressants and cognition in dementia 
In terms of improving cognition in people with dementia, there is little evidence to 
suggest that antidepressants have any effect. The DIADS, DIADS-II, and HTA-SADD 
trials of depression in dementia, all showed no effect on cognition in those 
randomised to sertraline or mirtazapine treatments compared with placebo treatment 
(Banerjee et al., 2013, 2011, Lyketsos et al., 2003, 2000a; Munro et al., 2004; 
Rosenberg et al., 2010). This has been echoed in other studies investigating the 
effects of other antidepressants (Choe et al., 2015; Levkovitz et al., 2001; Olafsson 
et al., 1992; Teri et al., 1991; Weintraub et al., 2010). There is some evidence to 
suggest that cognitive function (Petracca et al., 1996; Porsteinsson et al., 2014; Teri 
et al., 2000) or specific cognitive measures (Deakin et al., 2004; Reifler et al., 1989) 
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may be negatively impacted by some antidepressants.  However, a few trials also 
exist which have reported a significant improvement in cognitive performance 
following treatment compared to placebo (Mowla et al., 2007; Nyth et al., 1992; Roth 
et al., 1996). It is important to note however, that bar a few exceptions (e.g. Deakin 
et al., 2004; Mowla et al., 2007; Munro et al., 2012, 2004; Olafsson et al., 1992; Teri 
et al., 1991), most RCTs do not use a comprehensive cognitive battery. Instead 
many RCTs have explored cognition using a single global cognitive measure; 
typically the Mini Mental State Examination (MMSE). Cognition is a secondary 
outcome in these studies and the MMSE is used to primarily to describe the sample 
rather than as a discriminative outcome measure.  
 
Adverse events of antidepressants in dementia 
Whilst the effects of antidepressants on BPSD and other secondary outcomes in 
dementia are equivocal at best, it is clear that antidepressants cause a set of 
adverse events. Commonly occurring adverse events include: anxiety and 
nervousness (Auchus and Bissey-Black, 1997; Finkel et al., 2004), tremors (Auchus 
and Bissey-Black, 1997; Lanctôt et al., 2002), anorexia (Finkel et al., 2004; Moretti et 
al., 2002; Porsteinsson et al., 2014; Teranishi et al., 2013) and falls (Lanctôt et al., 
2002; Teranishi et al., 2013).  In addition, the level of adverse event reporting is high 
in absolute terms. HTA-SADD reported 43% of participants receiving sertraline and 
41% receiving mirtazapine showed adverse reactions compared to 26% on placebo 
(Banerjee et al., 2011). Porsteinsson and colleagues found 96% of participants 
taking citalopram had an adverse event (Porsteinsson et al., 2014), with diarrhoea, 
anorexia, fever, impaired cognition and QT interval prolongation significantly greater 
in the citalopram group compared to placebo. Despite the levels of adverse events 
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being high, study discontinuation appears relatively low and not higher in those 
receiving antidepressant treatment compared to placebo (9.0% vs 6.0% respectively) 
(Nelson and Devanand, 2011). 
 
DISCUSSION 
The findings from this narrative review of the literature suggest that despite being 
very commonly used, the evidence for antidepressants having a positive role in 
dementia is weak. A consistent finding is that any change observed in outcomes is 
also seen in the placebo group. There is no good evidence that antidepressants are 
effective in improving depression, ADL, cognition or carer burden. There are 
however harms that are attributable to the use of antidepressants, which are 
common and in some cases serious (Drye et al., 2014; Porsteinsson et al., 2014).  In 
view of these adverse effects, the lack of evidence for positive effects, and how 
commonly they are prescribed, further trials investigating the effect of withdrawing 
antidepressants in dementia from those where they have been used for long periods 
would be of value. 
 
To be clinically useful, studies need well defined and relevant sample populations. 
From this review it is apparent that many past trials have explored the effects of 
antidepressants on a large battery of secondary outcomes, in trials designed to test 
other hypotheses. However, there has been a positive move to greater 
methodological precision in recent trials of antidepressants in dementia (Banerjee et 
al., 2011; Porsteinsson et al., 2014; Rosenberg et al., 2010). This includes larger 
sample sizes with greater power, more generalisable study populations, correct use 
of blinding and placebo groups, greater specificity in the population chosen for study 
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(e.g. depression in dementia, agitation in dementia) and clarity in the primary 
outcomes, secondary outcomes and the measures chosen to assess them.  The 
data from such trials are much more likely to be of direct clinical relevance and to 
generate definitive results.  
 
It is important to note that there are several limitations of this review. First, whilst 
every attempt was made to identify the relevant literature by having broad search 
terms and searching citations, there is the possibility that some trials may have been 
missed. Second, this review did not exclude any study on the basis of their study 
quality, this may lead the significance of some findings to be over reported. We have 
attempted to account for this by putting a greater emphasis on larger studies, which 
have been judged to have a lower risk of bias.  
 
The lack of efficacy in treating BPSD with antidepressants is perhaps 
understandable when we consider that we are trying to treat a complex phenomenon 
with a simple intervention. Antidepressants that work in cognitively normal groups of 
older people with depression do not seem to work in those with depression in 
dementia. In part, this is likely to be due to greater heterogeneity in depression in 
dementia compared to depression without dementia. Dementia introduces multiple 
extra dimensions of complexity. Depression in dementia is likely to include at least 
three distinct groups: 
 
(i) A group where depression is situationally determined as a reaction to the 
impacts of dementia and may respond to problem solving and support. This is 
akin to ‘reactive’ depression and might respond to clinical support provided by 
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dementia diagnostic and care services rather than to antidepressants.  This 
would explain some of the positive change observed in those receiving 
placebo (but also usual care) in studies including DIADS-II and HTA-SADD.  
 
(ii) A homophenotypic group where the syndrome looks like depression but 
may have a different biological basis that is a function of the 
neurodegeneration of the dementia process. This group is likely to have a 
different neurochemistry compared with depression in those without dementia.  
This might explain the different (poorer) response to antidepressant treatment 
in those with depression in dementia. 
 
(iii) A group who carry a past history of depression (given it is a recurrent 
disorder) into dementia or who develop a ‘true’ episode of major depressive 
disorder in dementia.  In these cases antidepressant response may be similar 
to that in depression without dementia, but there might also be attenuation in 
treatment response due to the neurodegeneration and neurochemical 
changes that are part of dementia. 
 
There are data to support such heterogeneity. Zarb reported cognitively impaired 
patients with higher verbal intellectual functioning were more likely to be depressed 
(Zarb, 1996). This might be due to greater embarrassment and sadness at their 
memory decline or a greater awareness of their impairment.  Conversely, denial of 
memory deficits has been found to be negatively associated with depression 
(Sevush and Leve, 1993). People with depression in dementia have 
neuropathological differences compared to patients without depression including 
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degeneration of the locus coeruleus and substantia nigra (Zubenko and Moossy, 
1988) or the locus coeruleus and the central superior nucleus (Zweig et al., 1988). 
Degeneration of these nuclei are associated with deficits in noradrenaline and 
serotonin, both of which are related to mood (Zubenko et al., 1990; Zweig et al., 
1988). 
 
Research that seeks to develop treatments for AD and other dementias is 
increasingly aware of the complexity of these disorders, of the multiple aetiologies 
that may lead to these syndromes, and which may determine differential treatment 
response. These findings underline that this complexity is just as likely to be active in 
the BPSD that drive QoL in dementia, as in dementia itself. Current clinical practice 
in the use of antidepressants in dementia is more based in an altruistic desire to do 
something positive about BPSD whilst trying to avoid the harms that come from other 
drugs like antipsychotics, than it is based upon evidence.  
 
We need better treatments for BPSD. There are intriguing signals in the literature 
(such as the halving of carer time seen with mirtazapine in HTA-SADD and the 
positive effects on agitation in CitAD) that antidepressants may have a valuable role 
in their management.  We need to continue the programme of large good quality 
placebo-controlled RCTs following up leads from the literature to generate the 
evidence needed for us to be able to treat BPSD effectively and safely, maximising 
quality of life for those with dementia and their carers. 
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Table 1: A description of outcome measures related to RCTs identified in the review. Measures are not included if outcome data is not reported in relation to 
time or treatment effects of the antidepressant. 
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Banerjee et al., 
2013, 2011 (HTA-
SADD) 
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ZCBI 
DEMQOL, 
DEMQOL-
proxy, self-
rated EQ-5D, 
proxy-rated 
EQ-5D 
NPI  
 Bergh et al., 2012 
NPI*  NPI* CSDD NPI*  PSMS  
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AD carer 
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Choe et al., 2015 
   CSDD  
ADAS-cog, 
MMSE 
   NPI  
de Vasconcelos 
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 Fuchs et al., 1993 
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Gaber et al., 2001 
CMAI           
 Karlsson et al., 
2000 
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 Katona et al., 
1998 
   
MADRS, 
CSDD 
     GBS 
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CGI-I 
 Lanctôt et al., 
2002 
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BEHAVE-AD*, 
CMAI 
        
NPI, 
BEHAVE-AD 
 
 Lebert et al., 2004 
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 Lyketsos et al., 
2003; Munro et al., 
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Munro et al., 2012  
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Peters et al., 2015; 
Porsteinsson et al., 
2014  (CitAD) 
NPI*, CMAI, 
NBRS-A 
    MMSE ADCS-ADL 
NPI caregiver 
distress 
 NPI 
ADCS-
CGIC 
Petracca et al., 
1996 
 
   HDRS  MMSE FIM     
Petracca et al., 
2001 
 HAM-A  HDRS  MMSE FIM     
Pollock et al., 2002 
 
NBRS*  NBRS* NBRS* NBRS* MMSE      
Pollock et al., 2007  
NBRS*    NBRS*       
Reifler et al., 1989  
   HDRS  MMSE, DRS OARS     
Roth et al., 1996  
   HDRS  
MMSE, 
SCAG 
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Sultzer et al., 2001, 
1997 
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33 
 
 
Outcomes 
AUTHOR 
A
g
g
re
s
s
io
n
/ 
A
g
it
a
ti
o
n
 
A
n
x
ie
ty
 
A
p
a
th
y
 
D
e
p
re
s
s
io
n
 
P
s
y
c
h
o
s
is
 
C
o
g
n
it
io
n
 
F
u
n
c
ti
o
n
a
l 
C
a
re
g
iv
e
r 
B
u
rd
e
n
 
Q
o
L
 
G
lo
b
a
l 
B
P
S
D
 
C
li
n
ic
a
l 
S
e
v
e
ri
ty
 
Teranishi et al., 
2013 
NPI* NPI* NPI* NPI* NPI* MMSE FIM   NPI  
Teri et al., 1991 
     
MMSE, DRS, 
FOME, WMS-
AL, WMS-LM 
     
Teri et al., 2000  
CMAI, 
ABID 
    MMSE IADL SCB  
RMBPC
, BRSD 
ADCS-
CGIC 
 
*A specific items or subscales extracted.  
ABID = Agitated Behaviour in Dementia Scale, AChEIs = Acetyl Cholinesterase Inhibitors, AD = Alzheimer’s disease, ADAS-COG = Alzheimer’s Disease Assessment Scale – 
Cognitive Subscale, ADCS-ADL = Alzheimer’s Disease Cooperative Study- Activities of Daily Living Inventory, ADCS- GDS = Geriatric Depression Scale, ADFACS = 
Alzheimer’s Disease Functional Assessment and Change Scale, ADRQL = Alzheimer’s Disease Related Quality of Life, BADL = Bristol Activities of Daily Living, BEHAVE-AD 
= Behavior Pathology in Alzheimer's Disease Rating Scale, BGP = Rating Scale for Geriatric Patients, BPRS= Brief Psychotic Rating Scale, BPSD = Behavioural and 
Psychological Symptoms of Dementia, BRSD = Behavioral Rating Scale for Dementia, CANTAB = Cambridge Neuropsychological Test Automated Battery,  CBI = Caregiver 
Burden Inventory, CBQ = Caregiver Burden Questionnaire, CDR= Clinical Dementia Rating Scale, CGI-2= Clinical Global Impression item 2, CGI-I = Clinical Global 
Impression – Improvement Scale, CGI-S = Clinical Global Impression – Severity Scale, CGIC= Alzheimer’s Disease Cooperative Study – Clinical Global Impression of 
Change, CMAI = Cohen-Mansfield Agitation Inventory, CSDD = Cornell Scale for Depression in Dementia, CSI = Caregiver Stress Inventory, DLB = Dementia with Lewy-
Bodies, DRS = The Dementia Rating Scale, EOWPVT-R= Expressive One-Word Picture Vocabulary Test-Revised, FIM = Functional Independence Measure,   FOME = Fuld 
Object Memory Evaluation, GBS = Gottfries Brane Steen Scale,   GHQ-12= General Health Questionnaire-12, GS= Gestalt Scale, HAM-A = Hamilton Rating Anxiety Scale, 
HDRS = Hamilton Depression Rating Scale, HVLT-R= Hopkins Verbal Learning Test-Revised, IADL = Instrumental Activity of Daily Living, mADCS-CGIC = modified 
Alzheimer’s Disease Cooperative Study – Clinical Global Impression of Change, MADRS= Montgomery-Asberg Depression Rating Scale, MDD= Major Depressive Disorder, 
MMSE = Mini-mental state examination, NBRS = Neurobehavioral Rating Scale, NBRS-A = agitation subscale of the Neurobehavioral Rating Scale, NPI = Neuropsychiatric 
Inventory, PDRS-ADL = Psychogeriatric Dependency Rating Scale – Activities of Daily Living,  PSMS = Lawton and Brody’s Physical Self Maintenance Scale, QoL-AD = 
Quality of Life- Alzheimer’s Disease Scale, RBMT = The Rivermead Behavioural Memory Test, RMBPC = Revised Memory and Behaviour Problems Checklist, RSS = 
Relative Stress Scale, SCAG = Sandoz Clinical Assessment-Geriatric Scale, SCB = Screen for Caregiver Burden,  SDAT = Senile Dementia of Alzheimer’s Type, SF-12 = 
34 
 
Short Form-12 SIB = Severe Impairment Battery Scale, TPC = Ten Point Clock drawing test, VaD= Vascular Dementia,  WFp = Word Fluency Phonological Test, WFs = 
Word Fluency Semantic Test, WISC-R= Wechsler Intelligence Scale for Children-Revised,  WMS-AL = Wechsler Memory Scale-Associate Learning, WMS-LM = Wechsler 
Memory Scale- Logical Memory, ZCBI = Zarit Carer Burden Inventory. 
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Table 2: A description of identified RCTs and their results. All results are in relation to the effects of antidepressant treatment on outcome measures relevant 
to this review. Where possible the effects of the antidepressants are compared to a placebo or comparator group. 
AUTHOR 
(TRIAL 
NAME) 
NO. OF 
PARTICIPANTS 
TYPE OF 
PARTICIPANTS 
TREATMENT 
CONDITIONS 
DURATION RESULTS 
Auchus and 
Bissey-
Black, 1997  
15 
Dementia: Probable or 
possible AD  
BPSD: Agitation 
(CMAI ≥ 25) 
Fluoxetine (20 mg/day) 
Haloperidol (3 mg/day) 
Placebo 
6 weeks 
No treatment by time effect on CMAI (p=0.82), BEHAVE-AD 
(p=0.67), or CSI (p=0.67). 
Banerjee et 
al., 2011; 
2013 (HTA-
SADD) 
 
326 
Dementia: Probable or 
possible AD 
BPSD: Depression 
lasting  ≥4 weeks 
(CSDD>8) 
Sertraline (Target dose 150 
mg/day) 
Mirtazapine (Target dose 
45 mg/day) 
Placebo 
39 weeks 
Improvement in CSDD was found in sertraline, mirtazapine and 
placebo groups between baseline and endpoint (significance not 
reported). At endpoint no significant difference was reported 
between placebo and sertraline or mirtazapine (p>0.05): MMSE, 
BADL, NPI, DEMQOL, DEMQOL-proxy, self-rated EQ5D, proxy-
rated EQ5D, ZCBI, GHQ-12, SF-12 PCS, SF-12 MCS. 
Bergh et al., 
2012  
128 
Dementia: AD, VaD or 
mixed dementia 
BPSD: Presence of 
neuropsychiatric 
symptoms (but not 
depression) 
Treatment Discontinued: 
Escitalopram, Citalopram, 
Sertraline, Paroxetine 
Continued Treatment 
25 weeks 
Compared to those that discontinued treatment, CSDD was 
significantly lower (p=0.05) at 25 weeks. No significant difference 
was reported at 25 weeks between groups on measures of NPI 
(including psychosis, agitation and apathy clusters), PSMS, patient 
QoL-AD, carer QoL-AD, CDR or SIB (p>0.05). 
Choe et al., 
2015 
74 
Dementia: Probable 
AD (CDR 0.5-2) 
BPSD: Free from 
major depression or 
other major psychiatric 
illness. 
 
Escitalopram (20 mg/day) 
Placebo 
52 weeks 
There was a significant time effect for ADAS-Cog, MMSE, NPI but 
not CSDD. Escitalopram did not have a significant greater effect 
than the placebo group on any outcome measure (p>0.05). 
De 
Vasconcelos 
Cunha et al., 
2007 
31 
Dementia: Mild-
Moderate dementia 
(MMSE 10-24) 
BPSD: Major 
depression 
 
Venlafaxine (mean dose 75 
mg/day) 
Placebo 
6 weeks 
Significant time effect observed in MADRS score (p<0.001). No 
significant treatment effect in MADRS score or CGI scores. 
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AUTHOR 
(TRIAL 
NAME) 
NO. OF 
PARTICIPANTS 
TYPE OF 
PARTICIPANTS 
TREATMENT 
CONDITIONS 
DURATION RESULTS 
Deakin et 
al., 2004 
10 
Dementia:  Frontal 
variant frontotemporal 
dementia 
BPSD: No criteria 
Paroxetine (40  mg/day) 
Placebo 
9 Weeks 
 Reversal component of the visual discrimination task (p=0.05), the 
errors in the paired-associates learning task (p=0.06) and accuracy 
of the delayed pattern recognition memory (p=0.02) were impaired in 
the paroxetine group compared to placebo. NPI, CBI and other 
CANTAB measures did not significantly differ between groups 
(p>0.05). 
 
Drye et al., 
2011; 
Rosenberg 
et al., 2010; 
Martin et al.,  
2006; 
Weintraub et 
al., 2010 
(DIADS-II) 
131 
Dementia: Mild to 
Moderate AD (MMSE 
10-26) 
BPSD: "Depression of 
AD" 
Sertraline (Target dose 100 
mg/day) 
Placebo 
24 Weeks 
There were no significant differences on measures of mADCS-CGIC 
and CSDD at 12 weeks between sertraline and placebo groups 
(p>0.05).There was no treatment effect on mADCS-CGIC and 
CSDD scores at endpoint (p>0.05). NPI, ADRQL, ADCS-ADL and 
MMSE change scores did not significantly differ between treatment 
groups (p>0.05). 
Sertraline treatment was not superior to placebo at 24 weeks on 
mADCS-CGIC (p=0.48) or CSDD (p=0.90) in participants with major 
depression in dementia. No differences in between treatment groups 
for either outcome in those with minor depression or AD-associated 
affective disorder. 
 
Finkel et al., 
2004  
144 
Dementia: Probable or 
possible AD (MMSE 8-
23) 
BPSD: BPSD (NPI > 
5, Individual domain 
severity ≥ 2) 
Sertraline + Donepezil (50-
200 mg/day) 
Placebo + Donepezil 
12 weeks 
Change scores between baseline and endpoint were not significantly 
different between treatment groups on NPI, ADAS-COG, BEHAVE-
AD, CGI-I, CGI-S, CDR, HDRS, ADFACS, CMAI, CBQ or MMSE 
(p>0.05).For the CGI-I, a significant treatment by time interaction 
was reported on the linear mixed model (p=0.007).  
Fuchs et al., 
1993  
127 
Dementia: Primary 
degenerative dementia 
of senile onset (>65 
years) 
BPSD: Depression 
Maprotiline (25-75mg/day) 
Placebo 
8 weeks 
Video ratings of global impression, cognitive impression and 
depressive impressive were not significantly different between the 
treatment or placebo group. MMSE scores were not significantly 
different between treatment groups. GDS score improved 
significantly more in the maprotiline group in comparison to the 
placebo group (p = 0.09). Results were reported at the 10% 
significance level. 
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AUTHOR 
(TRIAL 
NAME) 
NO. OF 
PARTICIPANTS 
TYPE OF 
PARTICIPANTS 
TREATMENT 
CONDITIONS 
DURATION RESULTS 
Gaber et al., 
2001 
23 
Dementia: Probable 
AD, VaD or mixed 
dementia 
BPSD: “Agitation and 
behavioural 
disturbances” 
Sertraline (25-50 mg/day) 
Haloperidol (1-2 mg/day) 
10 weeks 
CMAI scores significantly improved in both the Sertraline and 
Haloperidol treatment arms (p<0.05). No significant differences were 
reported between the two treatment groups on CMAI scores. 
Karlsson et 
al., 2000 
336 (50 
dementia) 
Dementia: Dementia 
(MMSE 16-24) 
BPSD: Major 
depression of 
dysthymic disorder 
(MADRS ≥ 20) 
Citalopram (20-40 mg/day) 
Mianserin (30-60 mg/day) 
12 weeks 
MADRS total score on average decreased 12 points from baseline in 
the dementia sample regardless of treatment, there was no 
significant treatment effect (p>0.05). Those with dementia 
responded less well to treatment, as measured by MADRS, than 
those without dementia (p<0.04).  
Katona et 
al., 1998  
198 
Dementia: Dementia 
(MMSE 17-23) 
BPSD: Depression 
(MADRS ≥ 20) 
Paroxetine (Target dose 40 
mg/day) 
Imipramine (Target dose 
100 mg/day) 
8 weeks 
At endpoint, MADRS improved in both the paroxetine (M=12.6) and 
imipramine (M=11.8) groups; there was no significant difference 
between the two treatment groups at any time point (p> 0.05). CGI-S 
improved in both paroxetine (M=1.3) and imipramine (M=1.3) groups 
at endpoint, but there was no treatment effect at any time point 
(p>0.05). CGI-I improved at endpoint in both paroxetine (M=2.7) and 
imipramine (M=2.7) groups, though there were no treatment effects 
at any time point (p>0.05). CSDD improved at endpoint in both 
paroxetine (M=8.9) and imipramine (M=7.1) groups; there was a 
significant difference between treatment groups at week 4 and 8 
(p<0.05), but not at endpoint (p = 0.10). GBS improved at endpoint 
in both paroxetine (M=11.7) and imipramine (M=12.0), though there 
was no significant difference between the two groups at any time 
point (p>0.05). 
Lanctôt et 
al., 2002  
22 
Dementia: Probable 
AD (1 year duration, 
MMSE < 24) 
BPSD: Significant 
behavioural problems 
(NPI ≥ 8) 
Sertraline (100 mg/day) 
Placebo 
4 weeks 
There was no significant treatment effect on total NPI or CMAI at the 
end point of the study (p>0.05). No significant differences were 
reported between sertraline and placebo treatment on CMAI, NPI 
aggression subscale or BEHAVE-AD aggression subscale change 
scores (p>0.05).  
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AUTHOR 
(TRIAL 
NAME) 
NO. OF 
PARTICIPANTS 
TYPE OF 
PARTICIPANTS 
TREATMENT 
CONDITIONS 
DURATION RESULTS 
Lebert et al., 
2004  
 
26 
Dementia: FTD 
(FBDS > 3) 
BPSD: Total score NPI 
> 8 and one NPI item 
score of  ≥ 4 
Trazodone (Target dose 
300mg/day) 
Placebo 
12 weeks 
(cross over 
at week 6) 
Significant decrease in NPI total score after trazodone treatment 
compared to placebo (p<0.05) however a significant period (p<0.05) 
and sequence effect (p < 0.05) was observed.  Further analysis 
revealed that there was a treatment effect of select subscales of the 
NPI including depression (p=0.02) and agitation (p=0.04). No 
significant treatment effect was reported on MMSE, CGI-I, or any 
other relevant NPI subscale (p>0.05).   
Levkovitz et 
al., 2001  
 
20 
Dementia: AD 
BPSD:  Psychotic 
symptoms (BPRS ≥ 
18) lasting less than 6 
months.  
Fluvoxamine (50mg/day) + 
Perphenazine 
Placebo + Perphenazine 
6 weeks 
(crossover 
at week 3) 
Compared to the placebo group, BPRS scores significantly improved 
in the fluvoxamine group (p=0.03).There was also a significant 
positive effect of fluvoxamine on paranoid (p=0.03) and negative 
(p=0.02) symptoms items of the BPRS. There was no significant 
difference between groups on HDRS, CGI and BPRS (p>0.05).  
Lyketsos et 
al., 2000 
22 
Dementia:  Probable 
AD (MMSE>10) 
BPSD:  Major 
depressive episode 
Sertraline (Target dose 150 
mg/day) 
Placebo 
12 weeks 
CSDD significantly improved in the sertraline group at weeks 3, 6, 9, 
and 12 (p<0.05). The sertraline treatment was significantly better at 
improving CSDD compared to placebo (p=0.03). HDRS significantly 
improved in the sertraline group at weeks 3, 6, 9 and 12 (p<0.05). 
PDRS-ADL scores worsened in placebo group at weeks 9 and 12 
(p<0.05). There were no significant between group differences in 
HDRS, PDRS-ADL and MMSE measures. 
Lyketsos et 
al., 2003; 
Munro et al., 
2004 
(DIADS) 
44 
Dementia: Probable 
AD 
BPSD: Major 
depressive episodes 
Sertraline (Mean dose 95 
mg/day) 
Placebo 
12 weeks 
Depression symptoms improved in the sertraline treatment group. 
Both CSDD (p=0.002) and HDRS (p=0.01) significantly differed 
between treatment groups in favour of the sertraline treatment. 
There were no treatment effects on measures of NPI total, NPI 
caregiver distress, PDRS-ADL and MMSE (p>0.05). There was no 
treatment effect on the slope of decline over time on any cognitive 
measure (EOWPVT-R, HVLT-R, WISC-R, RBMT). 
Magai et al., 
2000 
31 
Dementia: Probable or 
possible AD 
BPSD: Minor and 
Major depression 
Sertraline (Target dose 100 
mg) 
Placebo 
8 weeks 
CSDD (p<0.0001) and GS (p<0.05) improved over time. There were 
no treatment by time interactions for CSDD, GS, CMAI, and sad face 
(p>0.05). The authors noted that the treatment by time interaction 
approached significance on the knit-brow face measure in favour of 
sertraline (p<0.10) 
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CONDITIONS 
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Moretti et 
al., 2002 
50 
Dementia: Probable 
AD (MMSE ≥ 12) 
BPSD: Not required 
AChEIs + Citalopram 
(Target dose 20 mg/day) 
AChEIs 
48 weeks 
 MMSE significantly declined from baseline in both treatment groups 
(p<0.05), however TPC, WFs, WFp and IADL scores remained 
unchanged (p>0.05). RSS, NPI and HDRS scores significantly 
improved between baseline and endpoint (p<0.01). Only RSS, NPI 
and HDRS scores were significantly lower in citalopram + AChEI 
group compared to AChEI only group at endpoint (p<0.01). 
Mowla et al., 
2007 
122 
Dementia Alzheimer 
type (MMSE 10-24) 
BPSD:  Not required 
Rivastigmine + Fluoxetine 
(20 mg/day) 
Rivastigmine 
Placebo 
12 weeks 
Those receiving fluoxetine reported a significant improvement in 
MMSE (p<0.001), WMS (p=0.007), ADL (p<0.001), HDRS (p<0.001) 
from baseline to endpoint. The MMSE (p=0.002), WMS (p<0.001) 
and ADL (p=0.001) change scores were all significantly improved in 
the fluoxetine group compared to the placebo group. CGI-2 scores 
were significantly better in the fluoxetine group compared to the 
placebo group (p<0.01). 
Munro et al., 
2012 
131 
Dementia: AD (MMSE 
10-26) 
BPSD: "Depression of 
AD" 
Sertraline (Target dose 100 
mg/day) 
Placebo 
24 Weeks 
There was no significant difference between sertraline and placebo 
group on any cognitive test performance at endpoint (p>0.05). 
Nyth and 
Gottfries, 
1990  
98 
Dementia: SDAT, AD 
or VaD 
BPSD:  Not required 
Citalopram (Target dose 30 
mg/day) 
Placebo 
4 weeks 
double 
blind 
8 weeks 
open trial 
4 weeks 
double 
blind 
MADRS score significantly declined between baseline and week 4 
(p<0.05), however there was no between group differences on 
MADRS improvement. 
CGI scores worsened in the placebo group (p<0.05) but remained 
unchanged in the citalopram group. Anxiety and depressed mood 
items of the GBS significantly improved in the citalopram group 
(p<0.05). Only depressed mood items of the GBS were significantly 
more improved in the citalopram group compared to placebo group 
(p<0.05). 
Nyth et 
al.,1992 
 
149 
Dementia: Mild-
Moderate dementia 
BPSD: Clinical 
depression (DSM III; 
Total HDRS ≥ 14) 
Citalopram (Target dose 
30mg/day) 
Placebo 
6 weeks 
In GBS items there was a significant improvement from baseline to 
endpoint in anxiety (p<0.01), depressed mood (p<0.001), orientation 
in time (p<0.05), personal orientation (p<0.05), recent memory 
(p<0.01) and distant memory (p<0.05). None of these measures 
significantly improved in the placebo group between time points.  A 
significant between group difference in improvement scores were 
reported for orientation in time and recent memory (p<0.05), and 
trending toward significance in depressed mood (p<0.06).  
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Olafsson et 
al., 1992 
46 
Dementia: Primary 
degenerative dementia 
or multi-infarct  
BPSD: Not required 
Fluvoxamine (150mg/day) 
Placebo 
6 weeks 
No significant time or treatment effects on any of the 
neuropsychological test scores, GBS scale scores or GBS subscale 
scores were observed. 
Peters et al., 
2015; 
Porsteinsso
n et al., 
2014 
(CitAD) 
186 
Dementia: Probable 
AD (MMSE 5-28) 
BPSD: Clinically 
significant agitation  
Psychosocial intervention 
+ Citalopram (Target dose 
30mg/day) 
Psychosocial intervention 
+ placebo 
9 Weeks 
The citalopram group showed significant improvement compared 
with placebo in the estimated difference in week 9 scores of NBRS-
A (p=0.04) and ADCS-CGIC (p=0.007). Compared to placebo, 
citalopram was associated with improved scores on the CMAI 
(p=0.008), NPI total (p=0.01), NPI agitation (p =0.12) and NPI 
caregiver distress (p=0.02). A significant negative effect was 
reported in those receiving citalopram compared to placebo for 
MMSE scores (p=0.03). There was no significant difference between 
groups on the ADCS-ADL scale (p=0.32). 
Petracca et 
al., 1996 
 
24 
Dementia: Probable 
AD 
BPSD: HDRS > 10 
Clomipramine (Target dose 
100mg/day) 
Placebo 
14 weeks 
(cross over 
after 6 
weeks RCT 
and a 2 
week wash-
out) 
Significant time effect on HDRS scores (p < 0.001) but participants 
taking clomipramine showed greater improvement during the first 6-
week treatment period (p < 0.01). Remission (HDRS ≤ 7) numbers 
were greater for participants started on clomipramine compared to 
those that started on placebo (p = 0.02). Significantly lower MMSE 
scores in the clomipramine group compared to placebo (p < 0.01). 
No significant treatment effects on FIM scores. 
Petracca et 
al., 2001 
 
41 
Dementia:  Probable 
AD BPSD:  Major or 
minor depression 
Fluoxetine (Target dose 40 
mg/day) 
Placebo 
6 Weeks 
HDRS scores improved in both groups over time (p<0.001), 
however, there was no significant group effect or group by time 
interaction (p>0.05). HAM-A scores improved in both groups over 
time (p<0.001), however there was no significant group or group by 
time interaction (p>0.05).FIM scores improved in both groups over 
time (p<0.001) however there was no significant group effect of 
group by time effect. MMSE scores showed no significant time, 
group or group by time interaction (p>0.05). 
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Pollock et 
al., 2002 
 
85 
Dementia: AD, VaD, 
mixed type, or 
dementia otherwise 
not specified 
BPSD:  One target 
symptom (NBRS ≥ 3) 
in agitation items or 
psychosis items 
Citalopram (Target dose 20 
mg/day) 
Perphenazine (Mean dose 
6.5 mg/day) 
Placebo  
17 days 
Only depression and apathy NBRS subscale scores did not 
significantly improve from baseline in the citalopram group (p>0.05). 
Cognition, agitation, and psychosis significantly all improved from 
baseline to endpoint (p<0.05). A significant difference between 
citalopram and placebo group were only reported in improvements in 
agitation and liability scores (p<0.05). 
Pollock et 
al., 2007 
 
103 
Dementia: AD, VaD, 
DLB, mixed, or 
dementia otherwise 
not specified 
BPSD:   One target 
symptom (NBRS ≥ 3) 
in agitation items or 
psychosis items 
Citalopram (Mean 
maximum dose 31.1 
mg/day) 
Risperidone (Mean 
maximum dose 1.36 
mg/day) 
12 weeks 
There was a significant decline in both NBRS agitation (p=0.05) and 
psychosis (p<0.004) scores in the citalopram treatment group. No 
significant difference was reported between treatment groups on 
either measure of agitation of psychosis (p>0.05). 
Reifler et al., 
1989  
61 
(28 dementia 
with 
depression, 
33 not 
depressed) 
Dementia: AD (MMSE 
≤ 25) 
BPSD: Depression 
(HDRS ≥ 15) 
Imipramine (mean daily 
dose 83 mg/day) 
Placebo 
6 weeks 
Those receiving imipramine showed no significant improvement in 
HDRS, MMSE and OARS scores compared to placebo (p>0.05). 
DRS scores declined more significantly in the placebo group 
compared to patients receiving placebo (p<0.01). 
Roth et al., 
1996 
694 (511 
dementia with 
depressive 
symptoms, 
183 
depression 
with cognitive 
decline) 
Dementia: Dementia 
or cognitive 
impairment (MMSE 11-
28) 
BPSD: Depression of 
Major Depressive 
Episode (GDS ≥ 5;  
HDRS ≥ 14 on first 17 
items) 
Maclobemide (400 mg/day) 
Placebo  
6 weeks 
Significantly greater mean improvements were seen in the 
moclobemide group compared with placebo on the HDRS (p=0.001), 
the cognitive disturbance items on SCAG (p=0.05) and MMSE 
(p=0.05) at 6 weeks. Improvement in total SCAG score and BGP in 
the maclobemide group did not significantly differ to placebo 
(p>0.05). 
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Sultzer et 
al., 1997; 
2001 
28 
Dementia: Dementia  
BPSD: Agitated 
behaviours (CMAI ≥ 41 
or individual item score 
≥ 6) 
Trazodone (mean dose 218 
mg/day) 
Haloperidol (mean dose 2.5 
mg/day) 
9 weeks 
There was a significant time effect on CMAI (p<0.001), OAS 
(p=0.005) and CGI scores (p<0.001), but no significant treatment or 
treatment by time effect (p>0.05).  Also, HDRS (p=0.005) and the 
delusion subscale of the BEHAVE-AD (p=0.01) improved over time 
in the trazodone group. However, there was no significant treatment 
effect at any time point on these measures (p>0.05).   
Taragano et 
al., 1997 
37 
Dementia: Probable 
AD 
BPSD: Major 
Depressive Syndrome 
Fluoxetine (10 mg/day) 
Amitriptyline (25 mg/day) 
6 Weeks 
HDRS improved from baseline to endpoint (M=25.3 vs M=16.7) in 
the in both groups (snr). There was no significant difference between 
the fluoxetine group compared to the amitriptyline group in terms of 
the number of participants that reported a >30% reduction on the 
HDRS or in the improvement in MMSE from baseline to endpoint 
(M=20.0 vs M=21.4; snr).  
Teranishi et 
al., 2013 
82 
Dementia:  AD, VaD 
and DLB (MMSE < 19)  
BPSD: One 
neuropsychiatric 
symptom (NPI> 4) 
Fluvoxamine (25-200 
mg/day) 
Risperidone (0.5-2.0 mg/ 
day) 
Yukukansan (2.5-7.5 g/day) 
8 Weeks 
NPI scores significantly improved over time in the fluvoxamine group 
(p<0.001). In all three treatment groups, only the delusion (p=0.012) 
and agitation (p<0.001) subscales of the NPI were significantly 
reduced at end point. No significant between group differences were 
reported on any NPI subscale (p>0.05). MMSE and FIM did not 
change significantly from baseline in the fluvoxamine group 
(p>0.05). 
Teri et al., 
1991 
61 (28 with 
MDD, 33 
without) 
Dementia: Primary 
Degenerative 
Dementia (MMSE ≤ 
25)  
BPSD: MDD  
Imipramine (mean dose 82 
mg/day) 
Placebo  
8 Weeks 
There were no significant time by group effects on measures of 
MMSE, DRS, WMS-AL, WMS-LM or FOME (p>0.05). 
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Teri et al., 
2000  
149 
Dementia: Probable or 
possible AD 
BPSD: 2 week or more 
history of agitated 
behaviours occurring 
at least once weekly 
Trazodone (Mean dose 200 
mg/day) 
Haloperidol (Mean dose 1.8 
mg/day) 
Behavioural management 
techniques 
Placebo 
16 weeks 
ADCS-CGIC outcomes did not significantly differ between placebo 
and trazodone groups at endpoint (p=0.99). MMSE change scores 
were significantly worse in the trazodone group compared to the 
BMT group (p<0.05). IADL change scores were worse in the 
trazodone group compared to placebo (p<0.05). ABID, CMAI, 
BRSD, RMBPC and SCB change scores in the trazodone group did 
not significantly differ to any other treatment group. 
 
ABID = Agitated Behaviour in Dementia Scale, AChEIs = Acetyl Cholinesterase Inhibitors, AD = Alzheimer’s disease, ADAS-COG = Alzheimer’s Disease Assessment Scale – Cognitive 
Subscale, ADCS-ADL = Alzheimer’s Disease Cooperative Study- Activities of Daily Living Inventory, ADCS- GDS = Geriatric Depression Scale, ADFACS = Alzheimer’s Disease Functional 
Assessment and Change Scale, ADRQL = Alzheimer’s Disease Related Quality of Life, BADL = Bristol Activities of Daily Living, BEHAVE-AD = Behavior Pathology in Alzheimer's Disease 
Rating Scale, BGP = Rating Scale for Geriatric Patients, BPRS= Brief Psychotic Rating Scale, BPSD = Behavioural and Psychological Symptoms of Dementia, BRSD = Behavioral Rating Scale 
for Dementia, CANTAB = Cambridge Neuropsychological Test Automated Battery,  CBI = Caregiver Burden Inventory, CBQ = Caregiver Burden Questionnaire, CDR= Clinical Dementia Rating 
Scale, CGI-2= Clinical Global Impression item 2, CGI-I = Clinical Global Impression – Improvement Scale, CGI-S = Clinical Global Impression – Severity Scale, CGIC= Alzheimer’s Disease 
Cooperative Study – Clinical Global Impression of Change, CMAI = Cohen-Mansfield Agitation Inventory, CSDD = Cornell Scale for Depression in Dementia, CSI = Caregiver Stress Inventory, 
DLB = Dementia with Lewy-Bodies, DRS = The Dementia Rating Scale, EOWPVT-R= Expressive One-Word Picture Vocabulary Test-Revised, FIM = Functional Independence Measure,   
FOME = Fuld Object Memory Evaluation, GBS = Gottfries Brane Steen Scale,   GHQ-12= General Health Questionnaire-12, GS= Gestalt Scale, HAM-A = Hamilton Rating Anxiety Scale, HDRS 
= Hamilton Depression Rating Scale, HVLT-R= Hopkins Verbal Learning Test-Revised, IADL = Instrumental Activity of Daily Living, mADCS-CGIC = modified Alzheimer’s Disease Cooperative 
Study – Clinical Global Impression of Change, MADRS= Montgomery-Asberg Depression Rating Scale, MDD= Major Depressive Disorder, MMSE = Mini-mental state examination, NBRS = 
Neurobehavioral Rating Scale, NBRS-A = agitation subscale of the Neurobehavioral Rating Scale, NPI = Neuropsychiatric Inventory, PDRS-ADL = Psychogeriatric Dependency Rating Scale – 
Activities of Daily Living,  PSMS = Lawton and Brody’s Physical Self Maintenance Scale, QoL-AD = Quality of Life- Alzheimer’s Disease Scale, RBMT = The Rivermead Behavioural Memory 
Test, RMBPC = Revised Memory and Behaviour Problems Checklist, RSS = Relative Stress Scale, SCAG = Sandoz Clinical Assessment-Geriatric Scale, SCB = Screen for Caregiver Burden,  
SDAT = Senile Dementia of Alzheimer’s Type, SF-12 = Short Form-12 SIB = Severe Impairment Battery Scale, TPC = Ten Point Clock drawing test, VaD= Vascular Dementia,  WFp = Word 
Fluency Phonological Test, WFs = Word Fluency Semantic Test, WISC-R= Wechsler Intelligence Scale for Children-Revised,  WMS-AL = Wechsler Memory Scale-Associate Learning, WMS-LM 
= Wechsler Memory Scale- Logical Memory, ZCBI = Zarit Carer Burden Inventory. 
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Table 3: A summary table of risk of bias assessments for each study. 
AUTHOR 
Randomisation Allocation 
Blinding of 
participant 
and 
personnel 
Blinding of outcome 
Incomplete 
outcome data 
Selective reporting Other sources of bias 
Auchus and Bissey-Black, 
1997  
? ? ? ? + + + 
Banerjee et al., 2011; 2013 
(HTA-SADD) 
 
+ + + + + + + 
Bergh et al., 2012  
+ + + + - + ? 
Choe et al., 2015 
+ ? + + + ? + 
De Vasconcelos Cunha et al., 
2007 
? ? ? ? - + + 
Deakin et al., 2004 
? ? ? ? + - + 
Drye et al., 2011; Rosenberg 
et al., 2010; Martin et al.,  
2006; Weintraub et al., 2010 
(DIADS-II) 
+ + + + + + + 
Finkel et al., 2004  
? ? ? ? + + ? 
Fuchs et al., 1993  
? ? ? ? + + + 
Gaber et al., 2001 
? ? ? ? ? - ? 
Karlsson et al., 2000 
? ? ? ? + + + 
Katona et al., 1998  
? ? ? ? + + + 
Lanctôt et al., 2002  
? ? ? ? + + + 
Lebert et al., 2004  
 
? ? ? ? ? + + 
Levkovitz et al., 2001  
 
? ? ? ? + - + 
Lyketsos et al., 2000 
? ? ? ? + + + 
Lyketsos et al., 2003; Munro 
et al., 2004 (DIADS) 
+ + ? ? + + + 
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Table 3: A summary table of risk of bias assessments for each study. 
AUTHOR 
Randomisation Allocation 
Blinding of 
participant 
and 
personnel 
Blinding of outcome 
Incomplete 
outcome data 
Selective reporting Other sources of bias 
Magai et al., 2000 
? ? ? + + + + 
Moretti et al., 2002 
- - - - + + + 
Mowla et al., 2007 
+ ? + + + + + 
Munro et al., 2012 
? ? + ? ? - + 
Nyth and Gottfries, 1990  
? ? ? ? ? + + 
Nyth et al.,1992 
 
? ? ? ? + + + 
Olafsson et al., 1992 
? ? ? ? + + + 
Peters et al., 2015; 
Porsteinsson et al., 2014 
(CitAD) 
+ + + + + + + 
Petracca et al., 1996 
 
? ? + ? + + + 
Petracca et al., 2001 
 
? ? + ? + + + 
Pollock et al., 2002 
 
? ? + ? + + + 
Pollock et al., 2007 
 
? ? + + + + + 
Reifler et al., 1989  
? ? ? ? + + + 
Roth et al., 1996 
? ? ? ? + + + 
Sultzer et al., 1997; 2001 
? ? ? ? ? + + 
Taragano et al., 1997 
? ? ? + - + + 
Teranishi et al., 2013 
+ ? - + + + + 
Teri et al., 1991 
? ? ? ? ? + + 
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Table 3: A summary table of risk of bias assessments for each study. 
AUTHOR 
Randomisation Allocation 
Blinding of 
participant 
and 
personnel 
Blinding of outcome 
Incomplete 
outcome data 
Selective reporting Other sources of bias 
Teri et al., 2000  
? ? ? ? + + + 
 
+ Low risk of bias  ? Unclear risk of bias  - High risk of bias 
 
